TP53 and intrahepatic cholangiocarcinoma: The ICC now recognizes an entity of “AML with mutated TP53” as a distinct subtype, whereas WHO5 has not yet included this as a unique group, despite noting the association of TP53 alterations with very poor outcomes (Table 1) [2,3,4].